Fig. 6
From: Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
a Evans blue and triphenyltetrazolium chloride staining of the heart across the treatment groups (Sham, Vehicle, ONO-solution, and ONO-NP). b, c The size of the area at risk of infarct (Infarct/AAR) was reduced significantly in the ONO-NP group compared to the other 3 groups. d The troponin I level in the plasma was lowest across the group. #Significantly smaller than in the sham, vehicle, and ONO-solution groups. AAR = area at risk. Reproduced from ref. 162
